TIAA CREF Investment Management LLC Has $4.67 Million Stake in Theravance Biopharma, Inc. (TBPH)

TIAA CREF Investment Management LLC lowered its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 6.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 126,686 shares of the biopharmaceutical company’s stock after selling 8,815 shares during the period. TIAA CREF Investment Management LLC owned approximately 0.24% of Theravance Biopharma worth $4,665,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. raised its position in shares of Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 3,407 shares during the last quarter. Harvest Management LLC bought a new position in shares of Theravance Biopharma during the first quarter valued at approximately $228,000. OMERS ADMINISTRATION Corp raised its position in shares of Theravance Biopharma by 31.9% in the first quarter. OMERS ADMINISTRATION Corp now owns 9,500 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 2,300 shares during the last quarter. Principal Financial Group Inc. bought a new position in shares of Theravance Biopharma during the first quarter valued at approximately $420,000. Finally, Parametric Portfolio Associates LLC raised its position in shares of Theravance Biopharma by 3.3% in the first quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock valued at $519,000 after buying an additional 456 shares during the last quarter. 84.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma, Inc. (TBPH) opened at 29.79 on Wednesday. The firm’s market cap is $1.59 billion. The company has a 50-day moving average of $37.73 and a 200 day moving average of $35.59. Theravance Biopharma, Inc. has a one year low of $23.80 and a one year high of $43.44.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.14) by $0.13. Theravance Biopharma had a negative net margin of 641.67% and a negative return on equity of 67.69%. The firm had revenue of $3.09 million during the quarter, compared to analysts’ expectations of $5.07 million. Equities research analysts expect that Theravance Biopharma, Inc. will post ($4.61) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was posted by [[site]] and is the sole property of of [[site]]. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at [[permalink]].

TBPH has been the subject of several research analyst reports. Cantor Fitzgerald initiated coverage on shares of Theravance Biopharma in a research report on Friday, June 16th. They issued an “overweight” rating and a $55.00 price objective for the company. ValuEngine raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Theravance Biopharma in a research report on Wednesday, August 2nd. Leerink Swann set a $47.00 price target on shares of Theravance Biopharma and gave the stock a “buy” rating in a report on Wednesday, May 10th. Finally, BidaskClub downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Four research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $41.13.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.